Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.55 |
| ▸ | CSNK1A1 | P48729 | 5/20 | 0.49 |
| ▸ | WIZ | O95785 | 1/20 | 0.48 |
| ▸ | IKZF2 | Q9UKS7 | 7/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20046261 | 1.00 | CRBN (0.55) | CRBNCSNK1A1WIZIKZF2DDB1 | |
| SCHEMBL32669075 | 0.94 | CRBN (0.52) | CRBNCSNK1A1WIZIKZF2DDB1 | |
| SCHEMBL31413474 | 0.94 | CRBN (0.52) | CRBNCSNK1A1WIZIKZF2DDB1 | |
| SCHEMBL30273649 | 0.92 | CRBN (0.54) | CRBNCSNK1A1WIZIKZF2DDB1 | |
| SCHEMBL20046226 | 0.92 | CRBN (0.54) | CRBNCSNK1A1WIZIKZF2DDB1 | |
| SCHEMBL30341676 | 0.88 | CRBN (0.64) | CRBNCSNK1A1IKZF2DDB1 | |
| SCHEMBL29126557 | 0.88 | CRBN (0.64) | CRBNCSNK1A1IKZF2DDB1 | |
| SCHEMBL31334312 | 0.88 | CRBN (0.49) | CRBNCSNK1A1WIZIKZF2DDB1 | |
| SCHEMBL31333342 | 0.88 | IKZF2 (0.55) | CRBNCSNK1A1WIZIKZF2DDB1 | |
| SCHEMBL20231489 | 0.88 | IKZF2 (0.51) | CRBNCSNK1A1WIZIKZF2DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581025-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Auron Therapeutics, Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024050078-A1 | PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | AURON THERAPEUTICS, INC. (US) | 2024-03-07 | — | — | WO | disclosed |